Xamic500 mg/5 ml

Xamic is an antifibrinolytic medicine used to prevent or reduce excessive bleeding in a range of clinical situations. Evidence and approval status vary by formulation (oral tablet vs. intravenous injection) and by indication:

• Heavy menstrual bleeding (menorrhagia): A well-established oral indication for cyclic heavy menstrual bleeding, taken only during the days of heaviest flow.
• Short-term prophylaxis in hemophilia: Established use (oral and intravenous) to reduce bleeding during and after tooth extraction in patients with hemophilia, usually combined with clotting factor replacement.
• Postpartum hemorrhage and trauma-related bleeding: Recommended by the WHO and supported by large trials (the WOMAN trial for postpartum hemorrhage and CRASH-2 for trauma) for intravenous use under hospital supervision, ideally started as early as possible after bleeding onset.
• Surgical bleeding: Used peri-operatively (e.g., cardiac, orthopedic, dental surgery) under specialist supervision to reduce blood loss and transfusion needs.
• Hereditary angioedema: Used per some guidelines as short-term or prophylactic therapy under specialist supervision when first-line agents are unavailable.

Use of Xamic for indications other than heavy menstrual bleeding, especially the injectable form, should always be directed and supervised by a physician in a clinical setting.

Formulations of Tranexamic Acid available in Bangladesh typically include: Oral tablet containing 250 mg or 500 mg of Tranexamic Acid as the active ingredient, with standard tablet excipients; and Injection containing 100 mg/mL Tranexamic Acid solution for intravenous use, commonly supplied as 500 mg/5 mL ampoules. Exact strengths and excipients vary by brand and manufacturer; always check the product label of the specific brand dispensed.

Xamic is a synthetic derivative of the amino acid lysine that acts as an antifibrinolytic (clot-stabilizing) agent. It is available as oral tablets and as an intravenous injection, and is used to prevent or control bleeding in a variety of medical, surgical, dental, and obstetric conditions. Xamic works by reducing the breakdown of existing blood clots rather than by promoting new clot formation, which distinguishes it from procoagulant or clotting-factor therapies.

Antifibrinolytic / systemic hemostatic agent.

Tranexamic Acid is a competitive inhibitor of plasminogen activation and, at higher concentrations, a noncompetitive inhibitor of plasmin. By binding to lysine-binding sites on plasminogen, it blocks the interaction of plasmin(ogen) with fibrin, preventing dissolution of the fibrin clot (fibrinolysis) and stabilizing clots at sites of bleeding.

Pharmacokinetics: Oral bioavailability is approximately 30-50%. Peak plasma concentrations occur roughly 1-3 hours after an oral dose. Protein binding is low (around 3%), and the drug distributes into most body tissues and crosses the placenta; it also enters breast milk and cerebrospinal fluid in small amounts. Tranexamic Acid is eliminated mainly unchanged by the kidneys via glomerular filtration, with an elimination half-life of approximately 2-3 hours in patients with normal renal function; this half-life is prolonged in renal impairment, requiring dose adjustment.

Xamic tablets may be taken with or without food; swallow whole with a full glass of water and do not crush or chew unless the product labeling specifically allows it. Doses should be spaced evenly through the day as directed. Intravenous Xamic must be given slowly by a trained healthcare professional, as rapid injection can cause hypotension or dizziness, and it is not intended for self-administration at home. Complete the full prescribed course, especially for short-term hemophilia prophylaxis around dental procedures.

Xamic has a small number of well-documented, clinically significant interactions:

• Combined hormonal (estrogen-containing) contraceptives and other prothrombotic drugs: Concurrent use increases the risk of thrombosis (blood clots); this combination should only be used if specifically advised and monitored by a physician.
• Factor IX complex concentrates or anti-inhibitor coagulant concentrates: Should not be combined with Xamic, as this significantly increases the risk of thrombosis.
• Thrombolytic agents (e.g., streptokinase, alteplase): Xamic may antagonize their fibrinolytic effect; concurrent use should be avoided unless directed by a specialist.
• Other solutions in the same IV line: Xamic injection should not be mixed with blood or with solutions containing penicillin, due to incompatibility.

Always inform the prescribing doctor or pharmacist about all other medicines, supplements, and hormonal contraceptives being used before starting Xamic.

Most people tolerate Xamic well. Reported side effects include:

• Common: Nausea, vomiting, diarrhea, abdominal discomfort, headache, back pain, muscle or joint pain, and mild dizziness.
• Less common: Fatigue, nasal congestion, skin rash or itching, and, with the injection, discomfort or mild hypotension if given too quickly.
• Rare but serious: Visual disturbances (blurred vision, changes in color perception) with prolonged use; hypersensitivity or allergic reactions; and, rarely, thromboembolic events such as deep vein thrombosis or pulmonary embolism - see Contraindications and Precautions and Warnings.

Seek prompt medical attention for symptoms such as leg swelling or pain, chest pain, shortness of breath, sudden vision changes, or signs of an allergic reaction while taking Xamic.

Pregnancy: Xamic crosses the placenta. It is used clinically, under direct medical and hospital supervision, for postpartum hemorrhage based on strong evidence, including the WHO-recommended WOMAN trial protocol. However, routine self-use of Xamic during pregnancy for other indications is not recommended without a doctor's explicit direction, as safety data for general use in pregnancy, particularly the first trimester, are limited. Never start or stop Xamic during pregnancy without consulting a physician.

Lactation: Xamic passes into breast milk in small amounts, roughly one-hundredth of the maternal blood concentration. Use during breastfeeding should only occur under medical advice, weighing the benefit to the mother against any potential risk to the infant.

Use Xamic with caution and under medical supervision in the following situations:

• Thrombosis risk: Because Xamic inhibits clot breakdown, it should be used cautiously in patients with a history of thromboembolic disease or risk factors for clotting, and never combined with hormonal contraceptives or other prothrombotic agents without physician guidance (see Interaction).
• Renal impairment: Dose must be reduced according to kidney function, as Xamic is excreted renally and can accumulate (see Dosage and Administration).
• Visual changes: Patients on long-term therapy should have periodic ophthalmologic evaluation, including color vision testing, as advised by their physician; discontinue and seek medical review if visual disturbances occur.
• Hematuria: Use with caution in upper urinary tract bleeding, as clot formation may cause ureteric obstruction.
• Hepatic disease: Use cautiously, as with any systemic hemostatic agent, under physician guidance.
• Seizure risk: High-dose intravenous Xamic, particularly in cardiac surgery, has been associated with seizures; dosing must follow specialist protocols.

Seek immediate medical attention for symptoms of a blood clot - leg swelling or pain, chest pain, shortness of breath, or sudden vision changes - while using Xamic.

Symptoms of Xamic overdose may include nausea, vomiting, diarrhea, abdominal pain, low blood pressure (particularly with rapid IV administration), and, in severe cases, an increased risk of thrombosis or seizures. Xamic is not effectively removed by hemodialysis. In case of suspected overdose, seek immediate medical attention; treatment is supportive and symptomatic and should be managed in a hospital setting under physician supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: No specific dose reduction is required based on age alone, but renal function should be assessed, as many older adults have reduced kidney function requiring dose adjustment (see Dosage and Administration).

Renal impairment: Dose reduction is required in proportion to the degree of impairment; see Dosage and Administration.

Hepatic impairment: Limited specific data are available; use with caution and physician supervision.

Pediatric patients: Use only under pediatric or physician guidance for approved indications such as hemophilia-related dental bleeding prophylaxis; see Pediatric Uses.

Pregnancy and breastfeeding: See Pregnancy and Lactation.

Duration of Xamic therapy depends on the indication: typically up to 4-5 days per menstrual cycle for heavy menstrual bleeding; 2-8 days for short-term hemophilia prophylaxis around dental extraction; a short course, often single or a few doses, for acute postpartum hemorrhage or trauma bleeding under hospital care; and as directed by the surgeon for peri-operative use. Long-term or repeated use beyond the indicated course should continue only under regular physician review, including periodic monitoring where advised, such as eye examinations.

Tranexamic Acid belongs to the antifibrinolytic class of medicines, specifically a synthetic lysine analogue and plasminogen activation inhibitor. It falls under the broader category of systemic hemostatic agents used to reduce or prevent bleeding.

Tranexamic Acid works by reversibly binding to lysine-binding sites on plasminogen, blocking its conversion to plasmin and preventing plasmin from binding to and breaking down fibrin. This stabilizes existing blood clots by inhibiting fibrinolysis, rather than by promoting new clot formation.

Not assigned a letter category under current FDA labeling (letter categories were replaced by the Pregnancy and Lactation Labeling Rule); established use in postpartum hemorrhage occurs under direct medical supervision, while use for other indications in pregnancy should only be physician-directed - see Pregnancy and Lactation.

Use of Xamic in children should be physician-directed. Established pediatric use includes short-term prophylaxis, typically 2-8 days, to reduce bleeding during and after dental extraction in children with hemophilia, generally dosed at approximately 10 mg/kg per dose (oral or IV, per protocol), often alongside clotting factor replacement. Xamic has also been used, under specialist supervision, for other pediatric bleeding conditions such as trauma-related hemorrhage or epistaxis, based on individualized clinical judgment. Routine use in children without medical supervision is not recommended.